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Cryopyrin-associated periodic syndrome (CAPS) is caused by gain-of-function NLRP3 
mutations. Recently, somatic NLRP3 mosaicism has been reported in some CAPS 
patients who were previously classified as “mutation-negative.” We describe here the 
clinical and laboratory findings in eight British adult patients who presented with symp-
toms typical of CAPS other than an onset in mid-late adulthood. All patients underwent 
comprehensive clinical and laboratory investigations, including analysis of the NLRP3 
gene using Sanger and amplicon-based deep sequencing (ADS) along with measure-
ments of extracellular apoptosis-associated speck-like protein with CARD domain (ASC) 
aggregates. The clinical phenotype in all subjects was consistent with mid-spectrum 
CAPS, except a median age at disease onset of 50 years. Sanger sequencing of NLRP3 
was non-diagnostic but ADS detected a somatic NLRP3 mutation in each case. In one 
patient, DNA isolated from blood demonstrated an increase in the mutant allele from 
5 to 45% over 12 years. ASC aggregates in patients’ serum measured during active 
disease were significantly higher than healthy controls. This series represents 8% of 
CAPS patients diagnosed in a single center, suggesting that acquired NLRP3 mutations 
may not be an uncommon cause of the syndrome and should be sought in all patients 
with late-onset symptoms otherwise compatible with CAPS. Steadily worsening CAPS 
symptoms in one patient were associated with clonal expansion of the mutant allele 
predominantly affecting myeloid cells. Two patients developed AA amyloidosis, which 
previously has only been reported in CAPS in association with life-long germline NLRP3 
mutations.
Keywords: cryopyrin-associated periodic syndrome, asc aggregates, aa amyloidosis, nlrP3 somatic mutation, 
mutant allele, il-1β
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inTrODUcTiOn
Cryopyrin-associated periodic syndrome (CAPS) is a domi-
nantly inherited autoinflammatory disease (AID) comprising 
three overlapping clinical entities of varying severity: familial 
cold autoinflammatory syndrome (FCAS) represents the 
mildest phenotype, Muckle–Wells syndrome (MWS) is of 
intermediate severity, and chronic infantile, neurological, 
cutaneous, and articular (CINCA) syndrome, also known as 
neonatal-onset multisystem inflammatory disease (NOMID), 
is most severe (1–5). The disease typically presents at birth 
or early infancy, characterized by recurrent episodes of fever, 
urticaria-like rash, arthralgia, myalgia, aseptic meningitis, 
and inflammatory eye manifestations. Up to 60% of patients 
with MWS suffer from progressive sensorineural hearing loss, 
usually beginning in adolescence, and up to 25% eventually 
develop AA amyloidosis as a complication of severe longstand-
ing inflammation, which leads to nephrotic syndrome, renal 
failure, and death (2).
Cryopyrin-associated periodic syndrome is caused by muta-
tions in the NLRP3 gene leading to enhanced activation of the 
NLRP3-inflammasome and overproduction of IL-1β (2–5). 
Typically, activation of the NLRP3-inflammasome occurs via 
two-signal model and numerous stimuli are known to be the 
trigger (6). The gain-of-function mutations in the NLRP3 gene 
decrease the threshold to activate the NLRP3-inflammasome by 
means of the reduction to only one stimulus (7).
Autosomal-dominant inheritance is readily apparent in about 
75% of patients with MWS and FCAS whereas de novo NLRP3 
mutations account for CINCA/NOMID in more than half of 
affected children. The apparently paradoxical absence of an 
NLRP3 mutation using traditional Sanger technology in other 
children with CINCA/NOMID has lately been elucidated in some 
cases through the application of highly sensitive genetic methods, 
including PCR-cloning and amplicon-based deep sequencing 
(ADS). Several studies have identified somatic mosaicism in the 
NLRP3 gene in children with CINCA/NOMID (8–11) and MWS 
(12), consistent with a mutation occurring during embryogen-
esis. However, NLRP3 mosaicism has lately also been reported 
in a 52-year-old woman and a 62-year-old man with recent onset 
of CAPS symptoms (13, 14), suggesting the mutational event 
occurred late in life. NLRP3 mosaicism can thus be associated 
with a spectrum of CAPS phenotypes and age at disease onset. An 
acquired CAPS-like disorder known as Schnitzler syndrome can 
very rarely develop in patients with low grade lymphoplasmacytic 
lymphoma, characterized by the presence of an IgM paraprotein 
and, intriguingly, myeloid-restricted somatic NLRP3 mosaicism 
has been reported in two patients who had been diagnosed to 
have Schnitzler syndrome (15).
We report here eight patients with somatic NLRP3 mosaicism, 
who presented in mid to late adulthood with symptoms consist-
ent with CAPS. None of these patients had a family history of 
similar illness and all had been completely healthy previously. 
Their clinical features and response to treatment are described in 
detail. To investigate the etiology and dynamics of the mutational 
event in our cohort, we studied samples from multiple tissues and 
were able to perform a time-course study in one patient.
PaTienTs anD MeThODs
Between 2005 and 2016, a clinical diagnosis of CAPS was sup-
ported by genetic findings in 100 adult patients referred to the UK 
National Amyloidosis Centre (NAC). In eight further subjects, 
the clinical diagnosis was not supported by Sanger sequencing; 
these patients subsequently underwent ADS analysis of the 
NLRP3 gene to investigate the possibility of mosaicism. All 
subjects underwent comprehensive clinical assessment including 
search for a monoclonal immunoglobulin, including immuno-
fixation of serum and urine to exclude Schnitzler syndrome, 
serial measurements of the acute phase reactants [serum amyloid 
A protein (SAA) and C-reactive protein (CRP)], and screening 
for AA amyloidosis on a renal biopsy and by clinical examination, 
renal function tests, and 123SAP scintigraphy.
Patients were asked to complete the QualityMetric SF36v2® 
Health Survey designed to measure functional health and well-
being from the patient’s perspective before starting treatment and 
at various time-points on treatment.
Informed consent was provided by all subjects, and the 
ethical approval for the study was obtained from Royal Free 
Hospital and University College Medical School Research Ethics 
Committee for this retrospective study (REC reference number 
06/Q0501/42) and was in accordance with the Declaration of 
Helsinki.
Molecular investigations in the eight 
“Mutation-negative” caPs Patients
DNA was isolated from whole blood in all patients. In six, we 
were able to obtain additional samples, including saliva, buccal 
epithelial cells, urine, fresh blood for isolation of circulating lym-
phocytes, and myeloid cells. Isolation of neutrophils, monocytes, 
and T and B lymphocytes was performed with magnetic nano-
particles (Stemcell Technologies, Inc., Manchester, UK) following 
the manufacturer’s protocol. DNA was extracted from isolated 
cells using Qiagen Investigator DNA extraction Kit (Qiagen Ltd., 
Manchester, UK).
NLRP3/CIAS1 (exons 3, 4, and 6) [NCBI RefSeqGene 
NC_000001.10 (LRG_197)] and NLRP12 (exon 3) [NCBI 
RefSeqGene NC_000019.9] genes were amplified by PCR and 
analyzed by Sanger sequencing using the protocol described 
previously (16). The chromatograms were analyzed on the ABI 
3130xl Genetic Analyser using Sequencing Analysis Software 
version 5.4.
Amplicon-based deep sequencing was performed to amplify 
all exons of the NLRP3 gene using specific pair primers as previ-
ously described (17). All PCR amplicons were deep sequenced 
(mean coverage 3,500×) on different platforms (GS Junior 454, 
PGM IonTorrent and Illumina MiSeq). The sequences were 
analyzed using the Amplicon Variant Analyzer software (Roche, 
Switzerland).
Detection of asc Protein aggregates  
and il-1β in serum
Extracellular ASC protein aggregates were measured as 
described elsewhere (Baroja-Mazo, 2014 #6909). Briefly, 
Table 1 | Clinical characteristics in the eight patients with late onset of cryopyrin-associated periodic syndrome caused by somatic mosaicism in the NLRP3 gene.
Patient clinical symptoms Duration of 
symptoms (years)/
age at diagnosis 
(years)
Median Pre-
treatment saa/
crP (mg/l)
Dna substitution/
protein variant 
(NCBI Ref Seq: 
NM_001243133.1)
MaF 
mean (%)
coverage 
of mutation 
mean (X)
1 UR, HF, BSD, conjunctivitis, headaches, papilledema 20/65–70 415/82 c.1688A > G/p.
Y563C
5.1 1,994
2 UR, HF, BSD, arthralgia, headaches, nausea, diarrhea, and 
marked lymphadenopathy
10/60–65 446/53 c.1688A > G/p.
Y563C
3.2 11,969
3 UR, HF, BSD, iritis, optic neuritis, papilledema, nephrotic 
syndrome, weight loss, AA amyloidosis
10/60–65 473/162 c.1688A > G/p.
Y563C
11.1 1,085
4 UR, HF, BSD, abdominal pain, fatigue, bilateral clubbing, 
nephrotic syndrome, weight loss, AA amyloidosis
20/65–70 79/42 c.1054G > A/p.
A352T
14.6 6,738
5 UR, HF, BSD, lymphadenopathy, conjunctivitis, died of 
pancreatic cancer
8/75–80 397/108 c.1706G > T/p.
G569V
21.1 2,535
6 UR, HF, BSD, conjunctivitis, fatigue, arthralgia, headaches, 
bilateral clubbing; papilledema chronic aseptic meningitis
10/50–55 121/54 c.1699G > A/p.
E567K
5.4 1,293
7 UR, HF, BSD, arthralgia and myalgia, conjunctivitis, and 
severe headaches.
20/50–55 276/291 c.1700 G > C/p.
E567Q
15 4,612
8 UR, HF, BSD, headaches, myalgia 15/65–70 Not done/146 c.1691G > A/p.
G564D
5.0 2,592
UR, urticaria-like rash induced by cold; HF, high-grade fever; BSD, bilateral sensorineural deafness; MAF, mutant allele frequency; SAA, serum amyloid A; CRP, C-reactive protein 
(normal range for SAA and CRP ≤ 10 mg/l).
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400  µl of plasma collected from 6 patients was incubated 
with 1  µg of rabbit polyclonal anti-ASC (Adipogen) at room 
temperature for 2  h, and another 400  µl of the same plasma 
samples were incubated in parallel with 1 µg of rabbit normal 
IgG, as non-specific staining control. Serum was centrifuged 
(2,500 ×  g ×  8  min), washed and the pellets were incubated 
for 1  h with 0.5  µg of anti-rabbit IgG Alexa Fluor 647 (Life 
Technologies). All samples were analyzed using a FACSCanto 
flow cytometer (BD) and FACSDiva software (BD) by gating for 
small particles based on forward scatter versus side scatter. A 
number of ASC protein aggregates per milliliter of serum were 
calculated after subtraction of non-specific staining samples. 
IL-1β was also quantified in the serum samples using a specific 
ELISA for human IL-1β (R&D), following the manufacturer 
instructions.
histology and immunohistochemistry
Six-micrometer-thick sections of kidney biopsies from patients 
3 and 4 who presented with nephrotic syndrome were stained 
for amyloid with Congo red and viewed under crossed polarized 
light (18). Confirmation of AA-type amyloid deposits was sought 
immunohistochemically using monoclonal antibodies specific to 
SAA (Euro-Diagnostica).
radiolabeled serum amyloid P 
component (saP) scintigraphy
Those two patients diagnosed with AA amyloidosis underwent 
whole body anterior and posterior scintigraphic imaging 24  h 
after administration of 123I-labeled SAP using a GE Infinia 
Hawkeye gamma camera, as previously described. The SAP 
results were interpreted by a panel of physicians with experience 
of over 30,000 SAP scans (19).
resUlTs
clinical characteristics in the eight 
subjects with somatic NLRP3 Mutations
The clinical features in this cohort are summarized in Table 1. 
The median age at disease onset was 50 years (range 31–71 years); 
median age at clinical diagnosis with CAPS was 65 years (range 
51–79 years) and the median duration of symptoms prior to refer-
ral was 15  years (range 8–20  years). All patients suffered with 
urticaria-like rash, which was most prominent on the trunk and 
legs, accompanied by fatigue and fevers and appeared to be much 
worse in the evenings and exacerbated by exposure to cold. All 
subjects had been diagnosed with progressive bilateral sensori-
neural hearing loss; four had conjunctivitis, three complained 
of frequent headaches, three had papilledema and one had optic 
neuritis. Baseline measurement revealed elevated inflammatory 
markers in all. Two patients developed AA amyloidosis compli-
cated by nephrotic syndrome prior to their referral to our center. 
None of these subjects had a family member suffering with simi-
lar symptoms. A potential diagnosis of Schnitzler syndrome was 
pursued in all cases but was excluded by absence of a circulating 
paraprotein.
Molecular investigations
Amplicon-based deep sequencing analysis revealed somatic 
NLRP3 mutation in eight patients (Table 1). Four novel variants 
were identified: p.Y563C in three unrelated patients (patient 1, 2, 
and 3) with a mean mutant allele frequency (MAF) of 5.1, 11.1, 
and 3.2% respectively; p.G569V in patient 5 with a MAF of 21.1%; 
p.E567Q in patients 7 with a MAF of 15%, and p.G564D with a 
MAF of 5%. Two previously described amino acid substitutions 
were detected: p.A352T and p.E567K in patients 4 and 6, respec-
tively, with a MAF of 14.6 and 5.4%.
FigUre 1 | Somatic NLRP3 mutations identified in eight late-onset cryopyrin-associated periodic syndrome (CAPS) patients. (a) Sanger chromatograms showing 
somatic NLRP3 mutations and mutant allele frequency (MAF) in each case. (b) An increase in the MAF from 5.1 to 27 and 45% detected in blood samples collected 
9 and 12 years apart in patient 1. (c) Schematic representation of the NLRP3 gene and the encoded cryopyrin protein showing the location of all mosaic mutations 
identified in this study (in black) and from previous publications (in green), mutations identified in all late-onset-mosaic CAPS patients are shown by *.
Table 2 | Frequency of the NLRP3 mutations identified among different cell populations established by amplicon-based deep sequencing.
isolated cells Patient 1 
p.Y563c
Patient 2 
p.Y563c
Patient 3 
p.Y563c
Patient 4 
p.a532T
Patient 5 
p.g569V
Patient 6 
p.e567K
Patient 7 
p.e567Q
Patient 8 
p.g564D
control 
p.a439V
MAF (%) in whole blood 5.1a; 27b; 45c 3.3 11.1 14.6 21.2 5.4 15 5.0 56.3
MAF (%) in neutrophils 36.2b 7.4 10.7 16.2 21.8 12.3 ND ND 53.2
MAF (%) in monocytes 44.8b 6.6 10.6 14.9 23.2 11.0 ND ND 55.2
MAF (%) in B cells 15.4b 0.6d 6.6 12.3 17 7.1 ND ND 54.2
MAF (%) in T cells 11.4b 0.4d 1.6 4.8 1.5 1.6 ND ND 52.1
MAF (%) in saliva 20.5b 6.1 12.3 14.9 14.3 3.1 ND ND 54.4
MAF (%) in buccal cells 20.5b 1.7 2.7 7.2 3.9 0.7d ND ND 47.1
MAF (%) in DNA isolated from other 
sources
0.6 in urined None None None None 0.4 in urined None None None
In Patient 1, DNA was isolated from blood samples obtained in a2004; b2013; and c2016.
dResults under the threshold of 1% were considered to be false positives.
ND, not done.
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In patients 3, 4, and 5, Sanger chromatograms revealed small 
peaks underneath the wild-type nucleotide in the relevant posi-
tions of the NLRP3 gene suggesting mosaicism, while in the 
remaining patients with MAF ≤5% the small peaks were initially 
regarded as background signal (Figure 1A).
analysis of Tissue Distribution  
of the NLRP3 Mutations
The frequency of the mutant allele was established by ADS in 
DNA extracted from whole blood, from isolated lymphocytes and 
myeloid cells, and from buccal epithelial cells, saliva, and urine 
(Table 2). The MAF was noticeably highest among neutrophils 
and monocytes (median 12.3 and 11%, respectively) when com-
pared to other DNA sources (median 4.9%).
Our control for this study was an adult patient who was 
heterozygous for the NLRP3 p.A439V mutation, which was 
inherited from her affected mother. The MAF was established 
at about 50% in all isolated cells (Table 2) and is consistent 
with the expected frequency of a germline heterozygous 
variant.
FigUre 2 | Response to IL-1 treatment in the eight patients with late-onset cryopyrin-associated periodic syndrome (CAPS) and somatic NLRP3 mosaicism. (a,b) 
Extracellular ASC protein aggregates measured in the serum of six patients collected before introduction of IL-1 blocking therapy (anakinra 100 mg/daily) and while 
on treatment (only serum samples with the SAA/CRP levels ≤10 mg/l were selected) compared to ASC specks measured in the serum obtained from healthy 
volunteers. (c) Response to IL-1 treatment in the eight patients with late-onset CAPS showing a reduction in the serum amyloid A protein (SAA) levels; in patient 1 
anakinra was discontinued and 150 mg/8 weekly of canakinumab was introduced resulting in a massive disease flare-up. (D) Quality of life before and while on 
treatment with anti-IL-1 treatment. Left panel: data from patient 1 who had relentlessly worsening clinical CAPS and required increasing doses of IL-1 inhibitor. Right 
panel: data from the remaining seven subjects; a comparison of the mean scores in each domain before and on-treatment shows improvement in seven domains. 
PF, physical function; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social function; RE, role emotional; MH, mental health. (e) Posterior 
images of the whole body radiolabeled serum amyloid P component (SAP) scintigraphies performed in patient 3 showing regression of amyloid deposits; on the left 
is a SAP scan taken during the first assessment and on the right a SAP scan obtained at a follow-up visit 5 years later.
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Dynamics of the MaF in a Patient  
with Progressive Disease
Patient 1 had been healthy until age 46 years when she presented 
with symptoms consistent with CAPS, which became progres-
sively more severe during 12  years of follow-up and required 
progressive up-titrations of her IL-1 inhibitor treatment. We 
performed a time-course study using blood samples obtained at 
the initial assessment in 2004 and subsequently in 2013 and 2016. 
ADS analysis revealed an increase in the MAF from a baseline of 
5.1% (2004), rising to 27% (2013) and 45% (2016). These data were 
in concordance with the results obtained with the Sanger method 
of DNA sequencing (Figures 1B). In this patient, the c.1688A > G 
transition among purified B and T lymphocytes, neutrophils and 
monocytes had frequencies of 15, 11, 36, and 45%, respectively, 
on the samples collected in 2013. Thus far, we have not observed 
this phenomenon in other patients from this cohort, noting that 
they have been followed up for a median of only 3 years to date.
Detection of asc Protein aggregates  
and il-1β in the serum
Extracellular ASC protein aggregates were measured in the serum 
collected from six patients with somatic NLRP3 mutations before 
and during the administration of IL-1 blocking therapy (at dif-
ferent intervals from 1 to 12 months after starting treatment and 
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up to 6 years in patient 1). A significantly higher abundance of 
ASC aggregates was detected in the serum of untreated patients 
when compared to the healthy volunteers (p = 0.008). Following 
effective IL-1 inhibition, serum ASC levels gradually decreased 
over time in patients whose inflammation remained suppressed 
(SAA/CRP levels ≤ 10 mg/l) (Figures 2A,B). In patient 1, who 
initially showed a good response to anakinra, the ASC concentra-
tion fell from pre-treatment values of 84,999 to 933/ml 6 months 
after treatment was commenced. The patient has subsequently 
relapsed, and the ASC specks levels measured over a 6-year 
period fluctuated between 1,500 and 5,333/ml. In all plasma 
samples analyzed, IL-1β concentration was below the detection 
threshold of the ELISA used in this study, corroborating previous 
reports (6, 20) where IL-1β in serum was found very low in serum 
samples of CAPS patients independently of disease activity.
laboratory and clinical response  
to il-1 blocking Therapy
All patients demonstrated remarkable clinical and biochemical 
responses to treatment with the recombinant IL-1 receptor antago-
nist (IL-1RA), anakinra (Kineret) administered by subcutaneous 
injections (100 mg/day) (Figure 2C). Overall, the quality of life 
had improved in our cohort (Figure  2D), including resolution 
of fever, headache, skin, and joint symptoms associated with a 
marked reduction of inflammatory markers, audiometric testing 
demonstrated hearing improvement in two patients (Patients 1 
and 3). Renal function in patients 3 and 4 with AA amyloidosis 
gradually improved over time; proteinuria resolved in both cases 
in association with regression of amyloid measured by SAP scintig-
raphy (Figure 2E). Patient 5, notable for having developed CAPS 
in his eighth decade, sadly died of pancreatic cancer 18 months 
after diagnosis and highly effective treatment of CAPS.
Patient 1 had a complex clinical course. The patient remained 
in remission for almost 6  years after anakinra was initiated. 
However, due to breakthrough symptoms, her anakinra therapy 
was progressively intensified to 300 mg/day. An attempt to switch 
from anakinra to the anti-IL-1β monoclonal antibody canaki-
numab (150 mg/8 weeks) resulted in a major disease flare requir-
ing hospital admission for sterile meningitis. Reintroduction of 
anakinra, up to 400 mg/day, in combination with prednisolone 
5–10 mg/day initially brought her CAPS back under control for 
a period; a further relapse responded partially to the addition 
of canakinumab to this treatment regimen. Most recently, still 
further disease progression has been well suppressed though 
a combination of IL-1 and IL-6 blockade comprising anakinra 
300  mg/day plus tocilizumab 4  mg/kg fortnightly. No serious 
infectious adverse events have occurred during 6 months of this 
novel combination anti-cytokine therapy.
DiscUssiOn
Cryopyrin-associated periodic syndrome is a very rare disease 
with an estimated prevalence of 1–2 cases per million. The causa-
tive NLRP3 gene mutation is usually inherited and, as a result, 
inflammatory symptoms typically become evident very early 
in life. CAPS is rarely considered among patients who present 
with compatible features in adult life (21). We describe here eight 
patients who developed CAPS at the median age of 50  years, 
with clinical features indistinguishable from inherited forms of 
the disease, including CNS inflammation and progressive sen-
sorineural hearing loss. Schnitzler syndrome, which can mimic 
CAPS, was excluded through an array of sensitive paraprotein 
studies. ADS analysis revealed somatic NLRP3 mutations in all 
cases. Two mutations (p.A352T and p.E567K) have previously 
been reported in two Japanese children diagnosed with MWS 
associated with somatic NLRP3 mosaicism (12) and in a single 
heterozygous patient with CINCA-NOMID assessed in our 
center. Four novel mutations were discovered: p.Y563C, interest-
ingly present in three unrelated subjects, p.G564D, p.E567Q, and 
p.G569V. These new mutations have not been reported in the 
1000 Genomes Project database and in the Exome Aggregation 
Consortium, suggesting their absence among the healthy popu-
lation. The discovery of p.Y563C in three unrelated patients is 
particularly intriguing; the tyrosine amino acid in residue 563 is 
relatively well conserved among different species, and a different 
missense mutation at this residue (p.Y563N) has been reported 
as a cause of CAPS in two patients (21). The NLRP3 mutations 
identified in our cohort and in the two previously reported late-
onset mosaic CAPS cases (13, 14) are located in close proximity 
within the NAD domain, implying this part of the gene might 
be a hotspot for somatic mutations (Figure  1C). This suggests 
that it is important to conduct a meticulous analysis of this part 
of the NLRP3 gene in all subjects who present in adult life with 
symptoms consistent with CAPS.
Somatic mosaicism is well described in the molecular pathol-
ogy of cancer and neurodegenerative diseases and recently has 
gained recognition as a cause of AIDs, including CAPS (8–14), 
SAVI syndrome (22), Blau syndrome (23, 24), and TRAPS (25). 
Thus far, studies of all mosaic CAPS patients (8–14) have shown 
that the timing of when the mutation occurs and their subsequent 
selection can vary greatly. A mutation acquired during the early 
stages of embryogenesis will cause mosaicism affecting all cells 
of the body and, with respect to pathogenic mutations in the 
NLRP3 gene, would be expected to be associated with onset of 
inflammatory disease in early life (8). By contrast, lineage-specific 
genetic variants indicate mutational events that have occurred at 
a later stage of fetal development or any time of life subsequently, 
resulting in tissue-limited mosaicism (26, 27). To investigate the 
timing, etiology and the dynamics of the mutational events in our 
patients, we examined DNA from a variety of different tissues, 
along with samples obtained serially over a median duration 
of 3 years (range 2–7) in five subjects and over 14 years in one 
patient. In one case, patient 2, the mutant allele was detected 
predominantly in cells of myeloid linage, which is consistent with 
the two previously reported late-onset CAPS cases caused by 
myeloid-restricted somatic NLRP3 mosaicism (13, 14). Analysis 
of mesodermal (leukocytes), ectodermal (buccal epithelial) cells, 
and endodermal (urinary epithelial) cells in five patients identified 
the mutant allele in several cell types, but at differing frequencies. 
With regard to leukocytes, the MAF was higher among myeloid 
cells in comparison to lymphocytes, in particular T cells. A plausi-
ble explanation for the difference in the MAF among myeloid and 
lymphoid cells, despite a common progenitor, could be at least in 
part due to impairment of the lymphoid lineage differentiation 
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and/or a selective increase of the myeloid lineage. Such lymphoid 
to myeloid shift is well documented in the bone marrow studies of 
elderly patients (28, 29). The low mutant allelic frequency seen in 
buccal cells is likely to represent contamination of the sample with 
leukocytes, also reported in other studies (14). Thus, we conclude 
that our results point to a truly late-onset mutational event at the 
level of a multipotent hematopoietic stem cell or common myeloid 
progenitor in the case of patient 2. Including the two previous 
reports (13, 14), there are now 10 patients diagnosed with CAPS 
in their mid-late adult life, caused by somatic NLRP3 mutations, 
but the precise mechanisms of this phenomenon are not known. 
Several studies have demonstrated that the incidence of somatic 
alternations increases with age (30) and can be caused by less 
effective DNA repair pathways and decrease in cellular diversity. 
On average, 1.3 ± 0.2 somatic exonic mutations are acquired per 
hematopoietic stem cell per decade (31). Hematopoietic progeni-
tor and stem cells, such as stem cells in other tissues, accumulate 
somatic mutations throughout the human lifespan, most of 
these are nonpathogenic and without functional consequence or 
potential to contribute to clonal expansion. Certain mutations, 
however, confer a survival advantage to the mutated cell and allow 
clonal expansion. In our cohort, proliferation of the somatically 
altered cell population had reached detectable fraction and 
although we are unclear on the precise mechanisms, it may be 
possible that other, co-existing somatic alternations may have 
driven the expansion of mosaic clone.
We had the opportunity to re-analyze the NLRP3 gene in 
patient  1, who is notable for having been the first “mutation-
negative” CAPS patient that we had encountered, and to date the 
only patient whose inflammatory disease severity has inexorably 
worsened. Studies on blood samples obtained at presentation and 
nine and 12 years subsequently demonstrated an increase in the 
frequency of the mutant allele from 5.1 to 45% over this period, 
completely in keeping with her progressive requirement for inten-
sification of IL-1 inhibiting therapy. Thus far, we have not observed 
this phenomenon in other patients in this cohort, all of whom 
have had shorter follow-up and none of whom have required up-
titration of their highly effective therapy. The clonal expansion of 
myeloid cells evident in patient 1 remains unclear but a potential 
explanation is that the affected cells have a selective survival 
advantage. Clonal non-malignant expansion of hematopoietic 
stem cells has recently been described in large scale sequencing 
studies in healthy adult subjects, in whom the frequency of clonal 
hematopoiesis increased from 1% in those over age 40 to about 10% 
by age 65 years (30, 32). The mechanism might involve somatic 
mutations in several cancer related genes which confer advantages 
to hematogical stem/progenitor cells such as cell renewal and 
clonal expansion (33), but these “driver mutations” do not seem 
to lead directly to hematopoietic malignancies (30). Given the 
high frequency of this phenomenon in the older population, we 
hypothesize that one or more of these “driver mutations” could 
have led to the apparent selective survival advantage by clonal 
expansion of NLRP3 mutated cells of the myelo-monocytic line in 
our patient. Stepwise progression occurs in other non-malignant 
clonal disorders, commonly including monoclonal gammopathy 
of undetermined significance, and we await with great interest 
longer term follow-up in our other patients.
Most of our patients had been very symptomatic for many years 
prior to diagnosis of CAPS, which facilitated their treatment with 
IL-1 blockade. As is the case in CAPS generally, inhibition of IL-1 
was magnificently effective in this cohort with late-onset disease, 
by and large completely suppressing their inflammatory disease. 
End organ damage improved in four cases, comprising hearing 
improvement in two patients and regression of AA amyloid-
associated renal dysfunction in two patients. AA amyloidosis 
is a life-threatening complication of CAPS, which hitherto has 
only been reported in patients with germline NLRP3 mutations. 
Amyloidosis complicating acquired CAPS is not inherently 
surprising since AA amyloid develops in a small proportion 
of all patients with a sustained acute phase response due to a 
longstanding inflammatory disorder, generally after 10–20 years 
duration, and low-level somatic NLRP3 mosaicism is evidently a 
cause of this. The incidence of AA amyloidosis is notably high in 
patients with inherited AIDs because the inflammatory disorder 
is lifelong. Since the nature of the causative underlying inflamma-
tory disorder is unclear in about one-fifth of patients who present 
with AA amyloidosis, and because CAPS can occur in the absence 
of characteristic rash, we recommend in-depth sequencing of all 
of the known inherited AID genes in all patients with AA amy-
loidosis of undetermined cause.
Despite CAPS being associated with a high level production of 
IL-1β, there is no correlation between active disease and circulat-
ing IL-1β, which is virtually undetectable in human plasma, even 
in patients with active CAPS (20). In our cohort presented here, 
we obtained an indirect evidence that CAPS is associated with 
an upregulated NLRP3-inflammasome activation by measuring 
levels of ASC aggregates in the patients’ serum. We have previ-
ously reported high circulating levels of ASC aggregates during 
inflammatory flares in CAPS patients with somatic NLRP3 
mutations (6) and describe here studies in our cohort before and 
during therapy with IL-1 inhibition. Extracellular ASC aggregates 
are important mediators of inflammation by recruiting and 
activating the NLRP3-inflammasome, including this pathway 
in NLRP3 wild-type cells leading to significant amplification 
of IL-1β release (6, 34). In our patients, the serum concentra-
tion of ASC aggregates measured during active disease (before 
administration of IL-1 blocking therapy) was significantly higher 
compared to that of healthy volunteers. Following treatment 
with IL-1 blockade, the ASC protein concentration was initially 
stable but gradually decreased over a 12-month period in patients 
whose CAPS related inflammation remained well suppressed, i.e., 
in those whose SAA and CRP concentration remained in the ref-
erence range. In patient 1, who had a complex clinical course, the 
ASC concentration fell during the first 6 months of IL-1 blocking 
treatment, but subsequently became elevated again in association 
with her various clinical relapses. These data indicate that the 
abundance of circulating ASC aggregates reflects inflammatory 
disease activity in CAPS but that remission must be sustained for 
some months before a fall in concentration occurs.
In conclusion, this study has identified somatic NLRP3 
mosaicism as the etiology of late onset but otherwise typical 
CAPS in 8% of patients seen in the adult UK national CAPS 
treatment service. The mechanisms underlying the observed 
differing frequency of the mutant allele among lymphocytes and 
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myeloid cells remains unclear, but may include selective survival 
advantage of certain mutated cell types and/or clonal expan-
sion of myeloid cell lines that may be unrelated to the acquired 
NLRP3 mutation. This study extends growing evidence that 
somatic NLRP3 mosaicism is not an uncommon cause of CAPS, 
which should be considered in patients with CAPS-compatible 
symptoms that start late in life.
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